Eli Lilly and Company operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eli Lilly and Company with three other
companies in this sector in the United States:
sales of $20.85 billion
of which 33%
Teva Pharmaceutical Industries Limited
of which 55%
was Generic Madicines), and
of which 100%
Eli Lilly and Company reported sales of $21.22 billion
December of 2016.
increase of 6.3%
versus 2015, when the company's sales were $19.96 billion.
Sales of Endocrinology saw an increase
that was more than double the company's growth rate: sales were up
14.9% in 2016, from
$7.04 billion to $8.08 billion.
Not all segments of Eli Lilly and Company experienced an increase in sales in 2016:
sales of Neurosciences fell 7.3% to $2.72 billion.
Eli Lilly and Company also experienced decreases in sales in
Animal Health (down 0.7% to $3.16 billion)